A Novel Platform for Programmable RNA Editing Through Trans-Splicing

Tech ID: 32784 / UC Case 2022-112-0

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20250283112 09/11/2025 2022-112
 

Brief Description

RNA editing offers an exciting opportunity to modify genetic information without permanently altering the underlying DNA. While conventional RNA splicing occurs naturally within a single RNA molecule (in cis), existing technologies have been limited in their ability to precisely modify RNA using separate RNA molecules.

Researchers at UC Berkeley have developed an innovative hybrid RNA technology that enables targeted RNA modification through trans-splicing, joining two distinct RNA molecules. The platform combines a programmable targeting region with a donor RNA to direct the modification of specific target transcripts.

By enabling RNA modification without permanent genomic changes, this technology offers several compelling advantages, including potentially reversible genetic modulation, greater flexibility in therapeutic design, and opportunities to correct or replace disease-associated RNA sequences. Its programmable architecture also creates opportunities for applications in genetic medicine, functional genomics, and the development of next-generation RNA therapeutics.

By bringing programmable editing to the RNA level, this technology opens a new frontier in genetic medicine, offering a potentially flexible and reversible alternative to permanent DNA editing.

Suggested uses

  • A new modality of genetic medicine: RNA editing through trans-splicing rather than conventional DNA editing.
  • Reversible genetic intervention: Potential to modify disease-associated transcripts without permanently changing the genome.
  • Programmable RNA replacement: Potential to go beyond gene silencing and enable targeted modification or replacement of RNA sequences.

Advantages

  • No permanent DNA modification: Alters RNA rather than the underlying genome.
  • Potential reversibility: RNA modifications are transient, offering opportunities for adjustable therapeutic intervention.
  • Programmable targeting: Targeting regions can be designed to recognize specific RNA transcripts.
  • RNA sequence replacement: Potential to replace or modify portions of a target transcript rather than simply suppressing its expression.
  • Expanded therapeutic possibilities: Could address disease mechanisms that are difficult to target through conventional gene editing.
  • No reliance on DNA double-strand breaks: Avoids risks specifically associated with DNA cleavage-based editing.

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As